Pyxis Oncology Taps MedImmune’s Herbst as Chief Scientific Officer

Sarah de Crescenzo

Sarah de Crescenzo

October 18th, 2019

Xconomy Boston —

Pyxis Oncology, an immuno-oncology company developing antibody drugs to restore activity to dysfunctional T cells, has appointed Ronald Herbst as its chief scientific officer. Herbst joins the Boston-based company from the AstraZeneca (NYSE: AZN) global biologics R&D arm, MedImmune, where he was vice president of research and development and head of oncology research.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com. Follow @sarahdc

Trending on Xconomy

Underwriters and Partners

Xpertise: Watch + Learn

Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Key indicators & expert insight from industry leaders
Xconomy

Tweets from https://twitter.com/Xconomy/lists/lifesci